Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

(2018) Jason J. Luke et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management

(2018) Aarti Asnani   Current Oncology Reports

Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases

(2018) Christine A. Garcia et al.   Journal for ImmunoTherapy of Cancer

Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature

(2017) S. Cuzzubbo et al.   EUROPEAN JOURNAL OF CANCER

Severe cytokine release syndrome in a patient receiving PD-1-directed therapy

(2017) Seth J. Rotz et al.   PEDIATRIC BLOOD & CANCER

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

(2017) Chipman RG Stroud et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Pathobiology of radiation myelopathy and strategies to mitigate injury

(2015) C S Wong et al.   SPINAL CORD

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations

(2015) Luis H. Camacho   Cancer Medicine

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

(2013) Charles G. Drake et al.   Nature Reviews Clinical Oncology

Radiation Dose–Volume Effects in the Spinal Cord

(2010) John P. Kirkpatrick et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Infliximab for the treatment of refractory scleritis

(2009) P. Doctor et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis

(2009) David R. Minor et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab

(2008) R. L. Johnston et al.   DIGESTIVE DISEASES AND SCIENCES